Virinder S. Parmar

Virinder S. Parmar


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2019 in Molecules
Verified
Journal Article
Open access
PDF file
YYYogesh Yadav
Yogesh Yadav
DSDeepti Sharma
Deepti Sharma
KKKumar Kaushik
Kumar Kaushik
VKVineet Kumar
Vineet Kumar
AJAmitabh Jha
Amitabh Jha
VPVirinder S. Parmar
Virinder S. Parmar
The synthesis of novel pyrazolylnucleosides 3a–e, 4a–e, 5a–e, and 6a–e are described. The structures of the regioisomers were elucidated by using extensive NMR studies. The pyrazolylnucleosides 5a–e and 6a–e were screened for anticancer activities on sixty human tumor cell lines. The compound 6e showed good activity against 39 cancer cell lines. In particular, it showed significant inhibition against the lung cancer cell line Hop-92 (GI50 9.3 µM) and breast cancer cell line HS 578T (GI50 3.0 µM).

23 October 2024 in Topics in Current Chemistry
Verified
Journal Article
Closed access
PDF file
SKSumit Kumar
Sumit Kumar
AAAditi Arora
Aditi Arora
RCRiya Chaudhary
Riya Chaudhary
RKRajesh Kumar
Rajesh Kumar
CLChristophe Len
Christophe Len
VPVirinder S. Parmar
Virinder S. Parmar

11 February 2026 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SKSumit Kumar
Sumit Kumar
RCRadhika Chaurasia
Radhika Chaurasia
GKGaurav Kumar
Gaurav Kumar
ASArun K. Sharma
Arun K. Sharma
IAIjaz Ahmed
Ijaz Ahmed
VPVirinder S. Parmar
Virinder S. Parmar
Biocompatible de novo indolylchalcones exhibit anti-platelet aggregation and nitric oxide-mediated effects. They show antiplatelet activity and accelerated diabetic wound healing, indicating promise for diabetic wounds and cardiovascular therapy.